Drug Profile
Curcumin liposomal - Signpath Pharma
Alternative Names: Diferuloylmethane; Lipocurc; Lipocurcumin; Liposomal curcuminLatest Information Update: 20 Mar 2023
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Signpath Pharma
- Class Anti-ischaemics; Antihistamines; Antivirals; Catechols; Chemopreventatives; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action CCR2 receptor antagonists; Chemokine CCL 5 inhibitors; Interleukin 1 inhibitors; Interleukin 6 inhibitors; Interleukin 8 inhibitors; Mast cell stabilisers; NF-kappa B inhibitors; Proto oncogene protein c-akt inhibitors; Toll-like receptor antagonists; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Glioblastoma
- No development reported Solid tumours
Most Recent Events
- 01 Mar 2023 Phase-I/II clinical trials in Glioblastoma (Newly diagnosed, Combination therapy, Late-stage disease) in USA (IV) (NCT05768919)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease, Recurrent) in Austria (IV, Infusion)
- 31 Oct 2019 SignPath Pharma intends to conduct further clinical trials of liposomal curcumin, in 2020